Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tourian

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
BMC Psychiatry|March 23, 2013
A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorderMichael R Liebowitz, Karen A Tourian, Eunhee Hwang, et al.
Psychopharmacology Bulletin|September 16, 2009
Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placeboSusan G Kornstein, Maurizio Fava, Qin Jiang, et al.
Applied Neurophysiology|January 1, 1988
Involuntary movements of the lower extremity following dorsal root entry zone lesions in a man treated for phantom limb painA Tourian, R Iacono, B Nashold, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|June 29, 2010
Desvenlafaxine and weight change in major depressive disorderKaren A Tourian, Claire Leurent, Jay Graepel, et al.
Journal of Psychiatric Practice|January 22, 2013
Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatientsNakao Iwata, Karen A Tourian, Eunhee Hwang, et al.
Expert Opinion on Drug Metabolism & Toxicology|November 12, 2010
Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitorAlice I Nichols, Karen A Tourian, Susanna Y Tse, et al.
The Primary Care Companion for CNS Disorders|October 7, 2011
A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorderKaren A Tourian, Bruno Pitrosky, S Krishna Padmanabhan, et al.
The Journal of Clinical Psychiatry|March 12, 2013
Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trialJoshua Z Rosenthal, Patrice Boyer, Cécile Vialet, et al.
Clinical Therapeutics|August 25, 2009
Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studiesKaren A Tourian, S Krishna Padmanabhan, James Groark, et al.
Journal of Cell Science|April 1, 1978
Transfer of human chromosomes via human minisegregant cells into mouse cells and the quantitation of the expression of hypoxanthine phosphoribosyltransferase in the hybridsA Tourian, R T Johnson, K Burg, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
BMC Psychiatry|March 23, 2013
A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorderMichael R Liebowitz, Karen A Tourian, Eunhee Hwang, et al.
Psychopharmacology Bulletin|September 16, 2009
Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placeboSusan G Kornstein, Maurizio Fava, Qin Jiang, et al.
Applied Neurophysiology|January 1, 1988
Involuntary movements of the lower extremity following dorsal root entry zone lesions in a man treated for phantom limb painA Tourian, R Iacono, B Nashold, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|June 29, 2010
Desvenlafaxine and weight change in major depressive disorderKaren A Tourian, Claire Leurent, Jay Graepel, et al.
Journal of Psychiatric Practice|January 22, 2013
Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatientsNakao Iwata, Karen A Tourian, Eunhee Hwang, et al.
Expert Opinion on Drug Metabolism & Toxicology|November 12, 2010
Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitorAlice I Nichols, Karen A Tourian, Susanna Y Tse, et al.
The Primary Care Companion for CNS Disorders|October 7, 2011
A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorderKaren A Tourian, Bruno Pitrosky, S Krishna Padmanabhan, et al.
The Journal of Clinical Psychiatry|March 12, 2013
Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trialJoshua Z Rosenthal, Patrice Boyer, Cécile Vialet, et al.
Clinical Therapeutics|August 25, 2009
Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studiesKaren A Tourian, S Krishna Padmanabhan, James Groark, et al.
Journal of Cell Science|April 1, 1978
Transfer of human chromosomes via human minisegregant cells into mouse cells and the quantitation of the expression of hypoxanthine phosphoribosyltransferase in the hybridsA Tourian, R T Johnson, K Burg, et al.
Pageof 4